| | Share | s | Value |
|--|--------------|------|------------|
| RIGHTS ^{†††} - 0.0% | | | |
| Consumer, Non-cyclical - 0.0% | | | |
| Elanco Animal Health, Inc.* | 50 | 5 \$ | - |
| Tobira Therapeutics, Inc.* | 14 | 1 | - |
| Omthera Pharmaceuticals, Inc.* | 8 | 6 | - |
| Oncternal Therapeutics, Inc.* | | 7 | _ |
| Total Consumer, Non-cyclical | | | _ |
| Communications - 0.0% | | | |
| Nexstar Media Group, Inc.* | 2,53 |) | - |
| Total Rights | | | |
| (Cost \$104) | | | _ |
| | Fac | | |
| | rac Amour | | |
| FEDERAL AGENCY NOTES ^{††} - 22.4% | | | |
| Federal Farm Credit Bank | | | |
| 0.45% (U.S. Prime Rate - 2.80%, Rate Floor: 0.00%) due 03/14/221 | \$ 4,000,00 |) | 4,013,638 |
| 0.39% (3 Month U.S. Treasury Bill Rate + 0.29%, Rate Floor: 0.00%) due 04/11/221 | 2,000,00 |) | 2,006,167 |
| 0.18% (1 Month USD LIBOR + 0.03%, Rate Floor: 0.00%) due 12/29/21 ¹ | 2,000,00 |) | 2,001,226 |
| 0.40% (U.S. Prime Rate - 2.85%, Rate Floor: 0.00%) due 08/30/221 | 1,000,00 |) | 1,003,356 |
| Federal Home Loan Bank | | | |
| 0.06% (3 Month USD LIBOR - 0.17%, Rate Floor: 0.00%) due 01/06/211 | 2,500,00 |) | 2,499,998 |
| Total Federal Agency Notes | | · | |
| (Cost \$11,501,620) | | | 11,524,385 |
| U.S. TREASURY BILLS ^{††} - 19.6% | | | |
| U.S. Treasury Bills | | | |
| 0.09% due 04/01/21 ² ,3 | 10,000,00 |) | 9,998,067 |
| 0.08% due 01/28/21 ³ | 91,00 |) | 90,996 |
| Total U.S. Treasury Bills | | | |
| (Cost \$10,088,715) | | | 10,089,063 |
| REPURCHASE AGREEMENTS ^{††,4} - 58.6% | | | |
| J.P. Morgan Securities LLC | | | |
| issued 12/31/20 at 0.06% | | | |
| due 01/04/21 ² | 16,776,87 | 9 | 16,776,879 |
| Barclays Capital, Inc. | .,,, | | -,, |
| issued 12/31/20 at 0.06% | | | |
| due 01/04/21 ² | 6,989,42 | 8 | 6,989,428 |
| BofA Securities, Inc. | | | |
| issued 12/31/20 at 0.06% | | | |
| due 01/04/21 ² | 6,471,69 | 2 | 6,471,692 |
| Total Repurchase Agreements | | | |
| (Cost \$30,237,999) | | | 30,237,999 |
| Total Investments - 100.6% | | | |
| (Cost \$51,828,438) | | \$ | 51,851,447 |
| Other Assets & Liabilities, net - (0.6)% | | | (284,475) |
| Total Net Assets - 100.0% | | \$ | 51,566,972 |

Total Return Swap Agreements

| Counterparty | Index | Financing Rate Pay | Payment Frequency | Maturity Date | Units | Notional Amount | Appreciation (Depreciation) |
|---------------------|-----------------------------|--------------------|-------------------|---------------|--------|-----------------|-----------------------------|
| OTC Equity Index Sw | ap Agreements ^{††} | | | | | | |
| Goldman Sachs | Russell 2000 Index | 0.34% (1 Week USD | | | | | |
| International | | LIBOR + 0.25%) | At Maturity | 02/18/21 | 10,228 | \$ 20,198,742 | \$ 141,693 |
| BNP Paribas | Russell 2000 Index | 0.24% (1 Month USD | | | | | |
| | | LIBOR + 0.10%) | At Maturity | 02/18/21 | 983 | 1,941,390 | 15,228 |
| Barclays Bank plc | Russell 2000 Index | 0.09% (1 Week USD | | | | | |
| • | | LIBOR) | At Maturity | 02/17/21 | 14,880 | 29,386,069 | (318,362) |
| | | | | | | \$ 51.526.201 | \$ (161.441) |

- Non-income producing security. .

 Value determined based on Level 1 inputs

 Value determined based on Level 2 inputs.

 Value determined based on Level 3 inputs.

 Value determined based on Level 3 inputs.

 Variable rate security. Rate indicated is the rate effective at December 31, 2020. In some instances, the effective rate is limited by a minimum rate floor or a maximum rate cap established by the issuer. The settlement status of a position may also impact the effective rate indicated. In some cases, a position may be unsettled at period end and may not have a stated effective rate. In instances where multiple underlying reference rates and spread amounts are shown, the effective rate is based on a weighted average.

 All or a portion of this security is pledged as equity index swap collateral at December 31, 2020.

 Rate indicated is the effective yield at the time of purchase.

 Repurchase Agreements.

LIBOR — London Interbank Offered Rate plc — Public Limited Company